Company Dossier · Health Care
Caris Life Sciences
- Russell 1000
What Caris Life Sciences is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $0.99 billion, up 87% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to March 31, 2026: $0.12 billion.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to March 31, 2026: $0.02 billion.SEC EDGAR filings (XBRL)
- Latest earnings call or results release (August 5, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 1 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed March 3, 2026): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $27.2 million on the open market.SEC Form 4
- 246 institutional managers reported a position at June 30, 2026 (+44 on the quarter before).SEC Form 13F
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Caris Life Sciences yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (CARIS LIFE SCIENCES, INC.)third_quarter 2026 · $0.2 million
- Oct 20, 2026LobbyingLobbying report (CARIS LIFE SCIENCES, INC.)third_quarter 2026
- Jun 30, 2026Private creditLoans held by business development companies (Caris Life Sciences, Inc.)$96.8 million at cost
- Jun 5, 20268-KShareholder vote resultsItem 5.07
- Apr 2, 20268-KMaterial agreement signedItem 1.01
- Apr 2, 20268-KMaterial agreement terminatedItem 1.02
- Mar 3, 202610-K
- May 23, 2025S-1
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Insmed INSM | $1.1B | −$0.8B | Jun 30, 2026 |
| Repligen RGEN | $0.8B | $0.1B | Jun 30, 2026 |
| Axsome Therapeutics AXSM | $0.8B | −$0.1B | Jun 30, 2026 |
| Arrowhead Pharmaceuticals ARWR | $0.7B | −$0.1B | Jun 30, 2026 |
| Halozyme HALO | $1.7B | $0.8B | Jun 30, 2026 |
| Moderna MRNA | $2.2B | −$1.2B | Jun 30, 2026 |
| Exelixis EXEL | $2.4B | $1.2B | Jul 3, 2026 |
| United Therapeutics UTHR | $3.1B | $1.1B | Jun 30, 2026 |
Identity
- SEC CIK
- 2019410